2. About IMARC
For more than 5 years, the International Market Analysis Research and Consulting Group has
been a leading advisor on management strategy and market research worldwide. We partner
with clients in all sectors and regions to identify their highest-value opportunities, address their
most critical challenges, and transform their businesses.
IMARC's information products include major market, scientific, economic and technological
developments for business leaders in pharmaceutical, industrial, and high technology
organizations. Market forecasts and industry analysis for biotechnology, advanced materials,
pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing
methods are at the top of the company's expertise.
IMARC’s tailored approach combines unfathomable insight into the dynamics of companies and
markets with close cooperation at all levels of the client organization. This ensures that our
clients achieve unmatchable competitive advantage, build more proficient organizations, and
secure lasting results.
imarc©

3. About The Report
IMARC’s new report “France Diabetes Market Forecast 2011-2016” provides an analytical
and statistical insight into the French diabetes market. The report provides both current and
future trends in the prevalence, demographical breakup, diagnosis and treatment of diabetes
in France. The report has segmented the French diabetes market into two segments – Insulin
and the Oral Antidiabetics market. For each of the aforementioned categories, the report
provides historical and future market sales of key classes, key companies, key drugs and key
molecules.
The research study serves as an exceptional tool to understand the market trends,
therapeutic structure, competitive structure and the outlook of the French diabetes market
till 2016. This report can serve as an excellent guide for investors, researchers, consultants,
marketing strategists and all those who are planning to foray into the French diabetes market
in some form or the other.
Key Questions Answered in this Report:
What is the size and demographical breakup of the diabetes population in France?
What are the current and future diagnosis and drug treatment rates of diabetes in France?
How has the diabetes market behaved since 2005 and what are the expected trends till
2016?
What has been the historical performance of the French Insulin market during 2005-2010
and its outlook till 2016?
What has been the performance of top classes, top players, top molecules and top drugs
in the Insulin market during 2005-2010?
What has been the historical performance of the Oral Antidiabetics market during 2005-
2010 and its outlook till 2016?
What has been the performance of top classes, top players, top molecules and top drugs
in the Oral Antidiabetics market during 2005-2010?
imarc©

4. Why should you buy this report?
Gain a deeper understanding about the prevalence, diagnosis and treatment of diabetes in
France and identify your potential patient pool.
Analyze the historical, current and future trends in the Insulin and Oral Antidiabetics
market to identify potential classes, drugs, partners and competitors for market entry and
expansion plans.
Develop Investment strategies by identifying companies that have been the biggest
winners and losers in the French Insulin and Oral Antidiabetics market.
Gain an insight into future market events such as biosimilars and new product launches.
Classes Covered:
Fast acting Insulins, Long acting Insulins, Intermediate and Fast acting Insulins, Intermediate
acting Insulins, Biguanides, Glitazone and Biguanide combinations, Biguanide and
Sulphonylurea combinations, Glinides, Sulphonylureas, Glitazones, DPP-IV Inhibitors, Glp-1
Agonists, Alpha-Glucosidase Inhibitors, DPP-IV Inhibitor and Biguanide combinations,
Glitazone and Sulphonylurea combinations, SGLT Inhibitors, SGLT Inhibitor and Biguanide
combinations, PTP1B Inhibitors and all other Oral Antidiabetic classes.
Information Sources:
Information has been sourced from both primary and secondary sources:
Primary sources include industry surveys and face to face/telephonic interviews with
physicians and industry experts.
Secondary sources include proprietary databases and search engines. These sources
include company websites and reports, books, trade journals, magazines, white
papers, Industry Portals, government sources and access to more than 4000 paid
databases.
Forecasting Methodology:
IMARC generates its product and market forecasts utilizing its extensive database of
macroeconomic and sector specific data. The initial baseline forecast is generated with the
most recent market data. After an initial baseline forecast, all future macroeconomic and
sector specific events and assumptions are taken into account to generate the final forecast.
imarc©

5. Table of Contents
1 Executive Summary ---------------------------------------------------------------------------------------------------- 10
2 Epidemiology ------------------------------------------------------------------------------------------------------------- 13
2.1 Total Diabetes Patients ----------------------------------------------------------------------------------------- 13
2.2 Patients by Gender ----------------------------------------------------------------------------------------------- 14
2.3 Patients by Age Group ------------------------------------------------------------------------------------------ 15
2.4 Diagnosed and Drug Treated Population ----------------------------------------------------------------- 16
3 Market Dynamics -------------------------------------------------------------------------------------------------------- 17
3.1 Diabetes Market --------------------------------------------------------------------------------------------------- 17
3.1.1 Current Trends (2005–2010) ------------------------------------------------------------------------------ 17
3.1.2 Market Forecast (2011-2016) ----------------------------------------------------------------------------- 18
3.2 Insulin Market ------------------------------------------------------------------------------------------------------ 19
3.2.1 Current Trends (2005-2010) ------------------------------------------------------------------------------ 19
3.2.1.1 Market by Class ------------------------------------------------------------------------------------------- 20
3.2.1.2 Market by Molecule -------------------------------------------------------------------------------------- 20
3.2.1.3 Top Players ------------------------------------------------------------------------------------------------ 22
3.2.1.4 Top Drugs -------------------------------------------------------------------------------------------------- 23
3.2.2 Forecast (2011-2016) --------------------------------------------------------------------------------------- 24
3.3 Oral Antidiabetics------------------------------------------------------------------------------------------------- 26
3.3.1 Current Trends (2005-2010) ------------------------------------------------------------------------------ 26
3.3.1.1 Market by Class ------------------------------------------------------------------------------------------- 28
3.3.1.2 Top Players ------------------------------------------------------------------------------------------------ 30
3.3.1.3 Top Drugs -------------------------------------------------------------------------------------------------- 32
3.3.2 Forecast (2011-2016) --------------------------------------------------------------------------------------- 34
imarc©

6. List of Figures
Figure 2-1: France: Number of Diabetes Patients* (in 000’s), 2010, 2015, 2020, 2025 & 2030................ 13
Figure 2-2: France: Breakup of Diabetes Patients by Gender (in 000’s), 2010, 2015, 2020, 2025 & 203014
Figure 2-3: France: Breakup of Diabetes Patients by Gender (in %) 2010, 2015, 2020, 2025 & 2030 ..... 14
Figure 2-4: France: Breakup of Diabetes Patients by Age Group (in 000’s), 2010, 2015, 2020, 2025 &
2030 ...................................................................................................................................................... 15
Figure 2-5: France: Breakup of Diabetes Patients by Age Group (in %) 2010, 2015, 2020, 2025 & 2030 15
Figure 2-6: France: Diagnosed & Drug Treated Share of Population Forecast (in %) 2010, 2015 & 2020 16
Figure 3-1: France: Diabetes Market (in Million US$), 2005-2010 ........................................................... 17
Figure 3-2: France: Diabetes Market: Breakup of Insulin and Oral Antidiabetics (in %), 2005-2010........ 17
Figure 3-3: France: Diabetes Market Forecast (in Million US$), 2011-2016 ............................................ 18
Figure 3-4: France Diabetes Market: Breakup of Insulin and Oral Antidiabetics (in %), 2011-2016.......... 18
Figure 3-5: France: Insulin Market (in Million US$), 2005-2010 .............................................................. 19
Figure 3-6: France: Breakup of Insulin Market by Class (in %), 2005-2010 ............................................. 20
Figure 3-7: France: Insulin Market: Share by Molecules (in %), 2005-2010 ........................................... 21
Figure 3-8: France: Insulin Market: Share of Key Players (in %), 2005-2010 ......................................... 22
Figure 3-9: France: Insulin Market: Sales of Key Drugs (in %), 2005-2010 ............................................. 23
Figure 3-10: France: Insulin Market Forecast (in Million US$), 2011-2016 .............................................. 25
Figure 3-11: France: Oral Antidiabetics Market, (in Million US$), 2005-2010 .......................................... 27
Figure 3-12: France: Oral Antidiabetics Market: Share by Class (in %), 2005-2010 ................................ 29
Figure 3-13: France: Oral Antidiabetics Market: Share of Key Players (in %), 2005-2010 ...................... 32
Figure 3-14: France: Oral Antidiabetics Market: Share of Key Drugs (in %), 2005-2010.......................... 33
Figure 3-15: France: Oral Antidiabetics Market Forecast (in Million US$), 2011-2016 ............................. 35
Figure 3-16: France: Oral Antidiabetics Market: Share by Class Forecast (in %), 2010-2016 .................. 36
imarc©

7. List of Tables
Table 1-1: France: Oral Antidiabetics & Insulin Definitions........................................................................ 8
Table 2-1: France: Diagnosed & Drug Treated Population (in Millions), 2010, 2015 & 2020 .................... 16
Table 3-1: France: Breakup of Insulin Market by Class (in Million US$), 2005-2010................................ 20
Table 3-2: France: Insulin Market: Sales by Molecule (in Million US$), 2005-2010 ................................ 21
Table 3-3: France: Insulin Market: Sales of Key Players (in Million US$), 2005-2010............................. 22
Table 3-4: France: Insulin Market, Sales of Top Drugs (in Million US$), 2005-2010 ................................ 23
Table 3-5: France: Oral Antidiabetics Market: Sales by Class (in Million US$), 2005-2010 ..................... 29
Table 3-6: France: Oral Antidiabetics Market: Sales of Key Players (in Million US$), 2005-2010 ........... 31
Table 3-7: France: Oral Antidiabetics Market, Sales of Top Drugs (in Million US$), 2005-2010 ............... 33
Table 3-8: France: Oral Antidiabetics Market, New Drug Launches (2011-2016) .................................... 34
Table 3-9: France: Oral Antidiabetics Market by Class Forecast, (in Million US$), 2010, 2013 & 2016 .... 36
imarc©

8. Prices and Order Information
Electronic Access Electronic Access CD-ROM Mail Delivery Hard Copy Mail Delivery
(Single User License) (Multi User License) (Single User License) (Single User License)
US$ 750 US$ 1300 US$ 900 US$ 900
For more information visit: http://www.imarcgroup.com/france-diabetes-market-forecast-2011-2016/
To buy the complete report or to get a free sample:
Call: +91-120-425-6531 (Asia), +44-844-774-9660 (Europe), +1-631-791-1145 (America)
Email:sales@imarcgroup.com